1 minggu yang lalu
Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Stock analysts astatine Zacks Research lowered their Q2 2026 EPS estimates for Denali Therapeutics successful a investigation study issued connected Wednesday, October 23rd. Zacks Research expert A. Chakraborty now expects that nan institution will gain ($0.75)…
This communicative appeared connected marketbeat.com, 2024-10-25 13:37:28.
English (US) · 
Indonesian (ID) ·